Short interest in KPTI has declined by 8% month-over-month, supporting the current bullish bias in the KPTI stock forecast among swing traders and momentum funds. Thanks to its core acumen, analysts rate shares a unanimous strong buy . Also, the average price target stands at a blistering $7.13. In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,093.00 in company stock. The KPTI stock forecast sees potential for collaborative partnerships in the oncology pipeline, which could deliver valuation re-rating if market sentiment sustains.